UBS AM’s Royalty Pharma RPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $147M | Buy |
4,076,999
+1,229,065
| +43% | +$44.3M | 0.03% | 456 |
|
|
2025
Q1 | $88.7M | Buy |
2,847,934
+226,048
| +9% | +$7.04M | 0.02% | 569 |
|
|
2024
Q4 | $66.9M | Sell |
2,621,886
-350,315
| -12% | -$8.94M | 0.02% | 604 |
|
|
2024
Q3 | $84.1M | Buy |
2,972,201
+174,874
| +6% | +$4.95M | 0.02% | 562 |
|
|
2024
Q2 | $73.8M | Buy |
2,797,327
+933,604
| +50% | +$24.6M | 0.02% | 527 |
|
|
2024
Q1 | $56.6M | Buy |
1,863,723
+379,518
| +26% | +$11.5M | 0.02% | 570 |
|
|
2023
Q4 | $41.7M | Buy |
1,484,205
+137,644
| +10% | +$3.87M | 0.02% | 635 |
|
|
2023
Q3 | $36.5M | Buy |
1,346,561
+189,561
| +16% | +$5.14M | 0.02% | 640 |
|
|
2023
Q2 | $41.7M | Hold |
1,157,000
| – | – | 0.02% | 598 |
|
|
2023
Q1 | $41.7M | Buy |
1,157,000
+66,299
| +6% | +$2.39M | 0.02% | 598 |
|
|
2022
Q4 | $43.1M | Buy |
1,090,701
+61,294
| +6% | +$2.42M | 0.02% | 588 |
|
|
2022
Q3 | $41.4M | Buy |
1,029,407
+92,791
| +10% | +$3.73M | 0.02% | 602 |
|
|
2022
Q2 | $39.4M | Sell |
936,616
-1,765
| -0.2% | -$74.2K | 0.02% | 597 |
|
|
2022
Q1 | $36.6M | Buy |
938,381
+22,699
| +2% | +$884K | 0.02% | 691 |
|
|
2021
Q4 | $36.5M | Buy |
915,682
+325,543
| +55% | +$13M | 0.01% | 731 |
|
|
2021
Q3 | $21.3M | Buy |
590,139
+16,704
| +3% | +$604K | 0.01% | 845 |
|
|
2021
Q2 | $23.5M | Buy |
573,435
+55,481
| +11% | +$2.27M | 0.01% | 852 |
|
|
2021
Q1 | $22.6M | Buy |
+517,954
| New | +$22.6M | 0.01% | 826 |
|